NEW YORK, April 30 /CNW/ - Pfizer Inc reported today that the Federal
Court of Appeal of Canada has reversed a lower court ruling that would have
permitted generic manufacturer Novopharm to launch a competitor product to
Celebrex. The appellate court issued an order prohibiting regulatory approval
of Novopharm's product in Canada until Celebrex's compound patent expires in
"Today's ruling is an important one not only for Pfizer, but also for
patients in Canada and elsewhere," said Pfizer General Counsel Allen Waxman.
"Without appropriate protection of intellectual property, Pfizer and other
research-based pharmaceutical companies would not be able to make the
tremendous investments required to develop new, life-saving medicines that are
so critical to public health."
Novopharm may seek to appeal the decision to the Supreme Court of Canada.
For further information:
For further information: Pfizer Inc Bryant Haskins, 212-733-8719